{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:50:23Z","timestamp":1772578223882,"version":"3.50.1"},"reference-count":24,"publisher":"Baishideng Publishing Group Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2015]]},"DOI":"10.3748\/wjg.v21.i6.1945","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T01:32:27Z","timestamp":1423791147000},"page":"1945","source":"Crossref","is-referenced-by-count":73,"title":["Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review"],"prefix":"10.3748","volume":"21","author":[{"given":"Michael S","family":"Broder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebaffd"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31826d3a17"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"ref4","unstructured":"Sandostatin LAR Depot [prescribing information]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; 2011. Accessed 7\/30\/14. Available from: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/<\/ext-link>."},{"key":"ref5","unstructured":"DistillerSR (Version 2.0). (2012) Ottawa, Ontario, Canada: Evidence Partners Incorporated. Available from: http:\/\/systematic-review.net<\/ext-link>."},{"key":"ref6","unstructured":"Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 2005;37:360-363."},{"key":"ref7","unstructured":"OCEBM Levels of Evidence Working Group. \"The Oxford 2011 Levels of Evidence\". Oxford Centre for Evidence-Based Medicine. Available from: http:\/\/www.cebm.net\/index.aspx?o=5653<\/ext-link>."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(10)82012-6"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh216"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31818adf4b"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31821f66b4"},{"key":"ref12","unstructured":"Chadha MK, Lombardo J, Mashtare T, Wilding GE, Litwin A, Raczyk C, Gibbs JF, Kuvshinoff B, Javle MM, Iyer RV. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res 2009;29:4127-4130."},{"key":"ref13","unstructured":"Costa L, Quintela A, Rodrigues T, Pinto A, Távora I. Somatostatin Analogues to Control Disease Progression in Neuroendocrine Tumors (NET): A Review of Patients’ Characteristics and Clinical Outcome. In: 3rd Annual ENETS Conference, March 22-24, 2006, Prague, Czech Republic. Available from: http:\/\/www.karger.com\/Article\/Pdf\/93339<\/ext-link>."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3275\/7869"},{"key":"ref15","unstructured":"Koumarianou A, Zilos A, Syrios J, Kanakis G, Antoniou S, Liaskos K, Dokou A, Pectasides D, Tsavaris N, Kaltsas G. Metronomic Combination Therapy Including Temozolamide, Bevacizumab and Somatostatin Analogue for the Treatment of Malignant Gastroenteropancreatic Neuroendocrine Tumors. In: 7th Annual ENETS Conference, March 11-12, 2010, Berlin, Germany. Available from: http:\/\/www.karger.com\/Article\/Abstract\/313935<\/ext-link>."},{"key":"ref16","unstructured":"Markovich A, Emelianova G, Gorbounova V, Bruzgin V, Orel N. Long Acting Octreotide in Pts with Disseminated Neuroendocrine Tumors. In: ESMO 2012 Congress, September 28-October 2, 2012, Vienna, Austria. Available from: http:\/\/annonc.oxfordjournals.org\/content\/supplemental<\/ext-link>."},{"key":"ref17","unstructured":"Valle JW, Clayton A, Danson S, Burgess A, Meehan M, Hawkins RE. The Use of Sandostation-LAR in the Treatment of Carcinoid Syndrome Experience from a Single Centre. In: 37th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 12-15, 2001, San Francisco, CA. Accessed December 2012. Available from: http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts<\/ext-link>."},{"key":"ref18","unstructured":"Weber JM, Feldman M, Kvols L, Strosberg JR. Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors. In: 48th American Society of Clinical Oncology (ASCO) Annual Meeting 2012, June 1-5, 2012, Chicago, IL. Available from: http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts<\/ext-link>."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse M, Tomassetti P, Weber M, Fogelman DR, Ramage J. A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs [abstract]. In: 2013 American Society of Clinical Oncology Annual Meeting; 2013 May 31-June 4; Chicago, IL. J Clin Oncol 2013;31 suppl:abstract 4031.","DOI":"10.1200\/jco.2013.31.15_suppl.4031"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpa.0000235302.73615.d4"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0062-9"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Strosberg JR, Bobiak S, Zornosa CC, Choti MA, Bergsland EK, Benson AB, Bloomston M, Kulke M, Shah MH, Ya JC. Dosing patterns for octreotide LAR in neuroendocrine tumor (NET) patients: NCCN NET outcomes database [abstract]. J Clin Oncol 2013;31 suppl:abstract 4142.","DOI":"10.1200\/jco.2013.31.15_suppl.4142"},{"key":"ref23","unstructured":"Xu Y, Shih YT, Leary C, Shen C, Yao JC. Dosing patterns of octreotide LAR among elderly patients with neuroendocrine tumors: Analysis of the SEER-Medicare database. In: 48th American Society of Clinical Oncology (ASCO) Annual Meeting 2012, June 1-5, 2012, Chicago, IL. Available from: http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts<\/ext-link>."},{"key":"ref24","unstructured":"Strosberg J, Weber J, Feldman M, Goldman J, Almhanna K, Kvols L. Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors. Gastrointest Cancer Res 2013;6:81-85."}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i6\/1945.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T23:55:36Z","timestamp":1598745336000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i6\/1945.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v21.i6.1945","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}